Clinical Trial Update: Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluated Rituximab for steroid-refractory chronic graft-versus-host disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Graft vs Host Disease | Phase 1, Phase 2 | Status: COMPLETED